A practical reference on c-Met signaling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
==== CAD/CAM technologies ==== Because most of the above techniques are limited when it comes to the control of porosity and pore size, computer assisted design and manufacturing techniques have been introduced to tissue engineering. First, a three-dimensional structure is designed using CAD software. The porosity can be tailored using algorithms within the software. The scaffold is then realized by using ink-jet printing of polymer powders or through Fused Deposition Modeling of a polymer melt. A 2011 study by El-Ayoubi et al. investigated "3D-plotting technique to produce (biocompatible and biodegradable) poly-L-Lactide macroporous scaffolds with two different pore sizes" via solid free-form fabrication (SSF) with computer-aided-design (CAD), to explore therapeutic articular cartilage replacement as an "alternative to conventional tissue repair". The study found the smaller the pore size paired with mechanical stress in a bioreactor (to induce in vivo-like conditions), the higher the cell viability in potential therapeutic functionality via decreasing recovery time and increasing transplant effectiveness.
The mental effects of GnRH modifiers are positive with treatment associated with significant improvements in multiple psychological measures, including global functioning, depression, and overall behavioral and/or emotional problems. In a two-year study published in January 2023, Chen et al. found that gender-affirming hormones for transgender and non-binary youth "improved appearance congruence and psychosocial functioning". Another study analyzing Dutch transgender youth completed by Catharina van der Loos et al. found that 98% of participants who started gender-affirming hormone treatment in youth continued using said treatment into adulthood. In February 2024, the American Psychological Association approved a policy statement supporting unobstructed access to health care and evidence-based clinical care for transgender, gender-diverse, and nonbinary children, adolescents, and adults, as well as opposing state bans and policies intended to limit access to such care. In May 2025, a two-year systematic review commissioned by the state of Utah as part of a ban on trans youth healthcare concluded that "The consensus of the evidence supports that the treatments are effective in terms of mental health, psychosocial outcomes, and the induction of body changes consistent with the affirmed gender in pediatric [gender dysphoria] patients. The evidence also supports that the treatments are safe in terms of changes to bone density, cardiovascular risk factors, metabolic changes, and cancer".
==== Epidermal receptor (Sense organ) ==== Epidermal receptors are abundant and distributed all over the epidermis. Each receptor shows a slightly elevated cuticle which covers a group of tall, slender and columnar receptor cells. These cells bear small hairlike processes at their outer ends and their inner ends are connected with nerve fibres. The epidermal receptors are tactile in function (mechanoreceptor) and can respond to touch, cuticle deformation, gravity and sound. They also respond to chemical stimuli (chemoreceptors). Earthworms are extremely sensitive to mechanical vibrations (e.g. trampling, earthquakes) which make them emerge from the soil and crawl at its surface, a reflex used by earthworm harvesters (e.g. fishers) to catch them easily.
=== Translational repression === The translation initiation factor eIF4E is tightly regulated by the fragile X mental retardation protein (FMRP), which controls the translation of specific mRNAs at synapses. FMRP interacts with CYFIP1, which directly binds eIF4E at a domain structurally analogous to those found in canonical 4E-binding proteins such as EIF4EBP1, EIF4EBP2, and EIF4EBP3. This interaction competitively inhibits eIF4G binding, thereby blocking assembly of the eukaryotic translation initiation complex and repressing translation. The FMRP–CYFIP1–eIF4E complex is further stabilized by dendritically localized, non-coding RNAs such as BC1, which enhance FMRP-CYFIP1 interactions and mediate recruitment to specific target mRNAs. This repressive complex is responsive to neuronal stimulation. Synaptic activity promotes the dissociation of CYFIP1 from eIF4E, thereby allowing eIF4G to bind and initiate translation. This mechanism enables dynamic, activity-dependent regulation of protein synthesis at the synapse, contributing to processes such as synaptic plasticity and learning. Since eIF4E is an initiation factor that is relatively low in abundance, eIF4E can be controlled at multiple levels. Regulation of eIF4E may be achieved at the levels of transcription, RNA stability phosphorylation, subcellular localization and partner proteins.
The Sam and Ann Barshop Institute for Longevity and Aging Studies is a basic and clinical research institute located on the Greehey Academic and Research Campus of the University of Texas Health Science Center at San Antonio (UTHSCSA). It is a leading institute in the United States in geriatrics research. The Barshop Institute ranks #1 in National Institute on Aging funding among Texas institutions and is highly ranked in the country in National Institute of Health funding. The scientific director of the institute has been Elena Volpi, M.D., PhD, FGSA since July 2023. In 2009, one of the research projects of the institute was announced by Science magazine as one of the top scientific discoveries of the year. The Barshop Institute is home to several prestigious National Institute on Aging (NIA) research centers and programs, including the Nathan Shock Center, the Claude D. Pepper Older Americans Independence Center, the Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies, and the Interventions Testing Program. Collectively, these NIH-supported initiatives advance the Institute's mission to uncover the biological mechanisms of aging, develop interventions that prevent or treat age-related diseases, and promote healthier aging across the lifespan.
Sources: en.wikipedia.org
SPR curves usually show a strong minimum. With the use of a combined chromium-gold film or other carefully chosen material combinations a sharp resonance maximum can be observed when exciting a surface plasmon in the Kretschmann configuration. This may be useful in sensors applications where a strong and sharp resonance above noise is required and less heat is desired at the surface.
== History and ideology == The RF was founded on 13 March 1962 in a merger of the Dominion Party (DP), defectors from the anti-Whitehead faction of the United Federal Party (UFP) and former members of the Southern Rhodesia Liberal Party. It was shaky and ideologically split in its early days, with its heterogeneous membership (ranging from advocates of more gradual transition to explicit segregation) united only in their opposition to then-Prime Minister Edgar Whitehead's plans for transition to majority rule, as well as the UK's demands for majority rule before independence. The party harnessed white anxieties of a Congo and Kenya-style majority rule scenario in its successful campaign for the 1962 Southern Rhodesian general election, pledging to keep power "in responsible hands", ensure Southern Rhodesian independence from the Federation, and thwart "this mad idea of a hand-over, of a sell-out of the European and his civilisation, indeed of everything he had put into his country". Its opposition to the UK government's demands for majority rule was so great that the RF-led government eventually declared unilateral independence in 1965. The RF had fifteen founding principles, which included the preservation of each racial group's right to maintain its own identity, the preservation of "proper standards" through meritocracy, the maintenance of the Land Apportionment Act, which formalised the racial imbalance in the ownership and distribution of land, opposition to compulsory racial integration, job protection for white workers, and the practice of Christianity.
The slides move alternately up and down the stylus so when the barb of one slide has caught and retracts, it pulls the stylus and the other barbed slide into the wound. When the other barb has caught, it also retracts up the stylus pulling the stinger further in. This process is repeated until the stinger is fully in and even continues after the stinger and its mechanism is detached from the bee's abdomen. When a female honey bee stings a person, it cannot pull the barbed stinger back out, but rather leaves behind not only the stinger, but also part of its abdomen and digestive tract, plus muscles and nerves. This massive abdominal rupture kills the honey bee. Honey bees are the only bees to die after stinging.
== Production in mainland China == Between the late 1990s and early 2000s, both consumption and production of melamine grew considerably in mainland China. By early 2006, melamine production in mainland China is reported to be in "serious surplus". Between 2002 and 2007, while the global melamine price remained stable, a steep increase in the price of urea (feedstock for melamine) has reduced the profitability of melamine manufacturing. Currently, China is the world's largest exporter of melamine, while its domestic consumption still grows by 10% per year. However, reduced profit has already caused other joint melamine ventures to be postponed there. Surplus melamine has been an adulterant for feedstock and milk in mainland China for several years now because it can make diluted or poor quality material appear to be higher in protein content by elevating the total nitrogen content detected by some simple protein tests. Actions taken in 2008 by the Government of China have reduced the practice of adulteration, with the goal of eliminating it. As a result of the Chinese milk scandal, court trials began in December 2008 for six people involved in adding melamine in food products, ending in January 2009 with two of the convicts being sentenced to death and executed.
Lymphocyte T-cell immunomodulator (LTCI) is an immune regulating polypeptide, which is a potent regulator of CD-4 lymphocyte production and function. It increases lymphocyte numbers and interleukin-2 (IL-2) production in animals. It is extracted from bovine thymus.
Sources: en.wikipedia.org
=== Tolerance === LSD shows significant tachyphylaxis, with tolerance developing 24 hours after administration. The progression of tolerance at intervals shorter than 24 hours remains largely unknown. Tolerance typically resets to baseline after 3–4 days of abstinence. Significant cross-tolerance occurs between LSD, mescaline and psilocybin. A slight cross-tolerance to DMT is observed in humans highly tolerant to LSD. Tolerance to LSD also builds up with consistent use, and is believed to result from serotonin 5-HT2A receptor downregulation. Researchers believe that tolerance returns to baseline after two weeks of not using psychedelics.
Also in the 1930s Walter Reppe, an industrial chemist and later board member of BASF, discovered a number of homogeneous catalytic processes, such as the hydrocarboxylation, in which olefins or alkynes react with carbon monoxide and water to form products such as unsaturated acids and their derivatives. In these reactions, for example, nickel tetracarbonyl or cobalt carbonyls act as catalysts. Reppe also discovered the cyclotrimerization and tetramerization of acetylene and its derivatives to benzene and benzene derivatives with metal carbonyls as catalysts. BASF built in the 1960s a production facility for acrylic acid by the Reppe process, which was only superseded in 1996 by more modern methods based on the catalytic propylene oxidation.
== History == Nemonapride was developed by scientists at Yamanouchi Pharmaceuticals via structural modification of the benzamide antiemetic and gastroprokinetic agent metoclopramide. It was first described in the scientific literature by 1980. The name nemonapride was first used by 1989 and this name was designated as its INNTooltip International Nonproprietary Name in 1991. The drug was launched in May 1991. However, other sources state that it was launched in 1997.
Data from NHANES surveys (1976–1980 and 2003–2006) show that the prevalence of obesity has increased: for children aged 2–5 years, prevalence increased from 5.0% to 12.4%; for those aged 6–11 years, prevalence increased from 6.5% to 19.6%; and for those aged 12–19 years, prevalence increased from 5.0% to 17.6%. In 2000, approximately 39% of children (ages 6–11) and 17% of adolescents (ages 12–19) were overweight and an additional 15% of children and adolescents were at risk of becoming overweight, based on their BMI. Analyses of the trends in high BMI for age showed no statistically significant trend over the four time periods (1999–2000, 2001–2002, 2003–2004, and 2005–2006) for either boys or girls. Overall, in 2003–2006, 11.3% of children and adolescents aged 2 through 19 years were at or above the 97th percentile of the 2000 BMI-for-age growth charts, 16.3% were at or above the 95th percentile, and 31.9% were at or above the 85th percentile. Trend analyses indicate no significant trend between 1999 and 2000 and 2007–2008 except at the highest BMI cut point (BMI for age 97th percentile) among all 6- through 19-year-old boys. In 2007–2008, 9.5% of infants and toddlers were at or above the 95th percentile of the weight-for-recumbent-length growth charts. Among children and adolescents aged 2 through 19 years, 11.9% were at or above the 97th percentile of the BMI-for-age growth charts; 16.9% were at or above the 95th percentile; and 31.7% were at or above the 85th percentile of BMI for age.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.